2seventy bio Inc. (TSVT)
2.50
-0.03 (-1.19%)
At close: Jan 28, 2025, 3:59 PM
2.50
-0.20%
After-hours Jan 28, 2025, 04:00 PM EST
undefined% (undefined)
| Bid | 2.41 |
| Market Cap | 129.23M |
| Revenue (ttm) | - |
| Net Income (ttm) | - |
| EPS (ttm) | -1.83 |
| PE Ratio (ttm) | -1.37 |
| Forward PE | n/a |
| Analyst | Hold |
| Ask | 2.73 |
| Volume | 91,333 |
| Avg. Volume (20D) | 348,316 |
| Open | 2.53 |
| Previous Close | 2.53 |
| Day's Range | 2.41 - 2.53 |
| 52-Week Range | 2.35 - 6.40 |
| Beta | undefined |
About TSVT
2seventy bio, Inc., a cell and gene therapy company, focuses on the research, development, and commercialization of treatments for cancer in the United States. Its products pipeline includes idecabtagene vicleucel; ide-cel or Abecma and bb21217; and CAR-T cell product candidates for the treatment of multiple myeloma. 2seventy bio, Inc. has a collaboration arrangement with Bristol-Myers Squibb Company. The company was incorporated in 2021 and is h...
Industry Biotechnology
Sector Healthcare
IPO Date Nov 3, 2021
Employees 274
Stock Exchange NASDAQ
Ticker Symbol TSVT
Website https://www.2seventybio.com
Analyst Forecast
According to 6 analyst ratings, the average rating for TSVT stock is "Hold." The 12-month stock price forecast is $11, which is an increase of 339.12% from the latest price.
Buy 50.00%
Hold 50.00%
Sell 0.00%
Next Earnings Release
2seventy bio Inc. is scheduled to release its earnings on Mar 4, 2025,
before market opens.
Analysts project revenue of $13.12M, reflecting a 22.80% YoY growth and earnings per share of -0.11, making a -90.09% decrease YoY.
Analysts project revenue of $13.12M, reflecting a 22.80% YoY growth and earnings per share of -0.11, making a -90.09% decrease YoY.
5 months ago
+8.21%
2seventy Bio shares are trading higher after the c...
Unlock content with
Pro Subscription
7 months ago
-4.26%
2seventy Bio shares are trading higher after the company announced the sale of its Hemophilia A candidate and MegaTAL to Novo Nordisk.
